Journal of Central Nervous System Disease最新文献

{"title":"Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry.","authors":"Pavel Potuznik, Jiri Drahota, Dana Horakova, Marek Peterka, Aneta Mazouchova, David Matyas, Zbysek Pavelek, Marta Vachova, Eva Recmanova, Ivana Stetkarova, Jana Libertinova, Jan Mares, Pavel Stourac, Marketa Grunermelova, Alena Martinkova, Jana Adamkova, Pavel Hradilek, Radek Ampapa, Michal Dufek, Eva Kubala Havrdova, Dominika Stastna","doi":"10.1177/11795735241262743","DOIUrl":"10.1177/11795735241262743","url":null,"abstract":"<p><strong>Background: </strong>Cladribine, a selective immune reconstitution therapy, is approved for the treatment of adult patients with highly active multiple sclerosis (MS).</p><p><strong>Objectives: </strong>Provide experience with cladribine therapy in a real-world setting.</p><p><strong>Methods: </strong>This is a registry-based retrospective observational cohort study. First, using data from the Czech nationwide registry ReMuS, we analysed patients who initiated cladribine from September 1, 2018 to December 31, 2021. Second, we analysed a subgroup of patients who initiated cladribine between September 1, 2018 to June 30, 2020, thus possessing a follow-up period of at least 2 years. We evaluated demographic and MS characteristics including disease-modifying therapies (DMTs) before and after cladribine administration, relapses, Expanded Disability Status Scale (EDSS), and adherence.</p><p><strong>Results: </strong>In total, 617 patients (335 with follow-up of at least 2 years) started cladribine therapy in the study period (mean age 37.0, mean disease duration 8.4 years, 74.1% females). In most cases, cladribine was administered as a second-line drug, a total of 80.7% had been escalated from a platform DMT. During 2 years before cladribine initiation, the average annualised relapse rate (ARR) was .67. Following cladribine initiation, the ARR decreased to .28 in the first year and .22 in the second year. Overall, across the entire two-year treatment period, 69.0% of patients were relapse-free and the average ARR was .25. As for EDSS development, the median baseline EDSS was 2.5 and remained stable even after 24 months. The adherence to treatment ranged of around 90%.</p><p><strong>Conclusion: </strong>This nationwide study confirms the efficacy of cladribine in real-world settings, especially in patients who are not treatment-naïve. In addition, the study shows an exceptionally high adherence rate, a finding that underscores the invaluable role of cladribine, but also the value of registry-based studies in capturing real-world clinical practice.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241262743"},"PeriodicalIF":2.6,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI-informed machine learning-driven brain age models for classifying mild cognitive impairment converters.","authors":"Hanna Lu, Jing Li","doi":"10.1177/11795735241266556","DOIUrl":"10.1177/11795735241266556","url":null,"abstract":"<p><strong>Background: </strong>Brain age model, including estimated brain age and brain-predicted age difference (brain-PAD), has shown great potentials for serving as imaging markers for monitoring normal ageing, as well as for identifying the individuals in the pre-diagnostic phase of neurodegenerative diseases.</p><p><strong>Purpose: </strong>This study aimed to investigate the brain age models in normal ageing and mild cognitive impairments (MCI) converters and their values in classifying MCI conversion.</p><p><strong>Methods: </strong>Pre-trained brain age model was constructed using the structural magnetic resonance imaging (MRI) data from the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) project (N = 609). The tested brain age model was built using the baseline, 1-year and 3-year follow-up MRI data from normal ageing (NA) adults (n = 32) and MCI converters (n = 22) drew from the Open Access Series of Imaging Studies (OASIS-2). The quantitative measures of morphometry included total intracranial volume (TIV), gray matter volume (GMV) and cortical thickness. Brain age models were calculated based on the individual's morphometric features using the support vector machine (SVM) algorithm.</p><p><strong>Results: </strong>With comparable chronological age, MCI converters showed significant increased TIV-based (Baseline: <i>P</i> = 0.021; 1-year follow-up: <i>P</i> = 0.037; 3-year follow-up: <i>P</i> = 0.001) and left GMV-based brain age than NA adults at all time points. Higher brain-PAD scores were associated with worse global cognition. Acceptable classification performance of TIV-based (AUC = 0.698) and left GMV-based brain age (AUC = 0.703) was found, which could differentiate the MCI converters from NA adults at the baseline.</p><p><strong>Conclusions: </strong>This is the first demonstration that MRI-informed brain age models exhibit feature-specific patterns. The greater GMV-based brain age observed in MCI converters may provide new evidence for identifying the individuals at the early stage of neurodegeneration. Our findings added value to existing quantitative imaging markers and might help to improve disease monitoring and accelerate personalized treatments in clinical practice.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241266556"},"PeriodicalIF":2.6,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic polymorphisms and post-stroke upper limb motor improvement - A systematic review and meta-analysis.","authors":"Sandeep K Subramanian, Riley T Morgan, Carl Rasmusson, Kayla M Shepherd, Carol L Li","doi":"10.1177/11795735241266601","DOIUrl":"https://doi.org/10.1177/11795735241266601","url":null,"abstract":"<p><strong>Background: </strong>Post-stroke upper limb (UL) motor improvement is associated with adaptive neuroplasticity and motor learning. Both intervention-related (including provision of intensive, variable, and task-specific practice) and individual-specific factors (including the presence of genetic polymorphisms) influence improvement. In individuals with stroke, most commonly, polymorphisms are found in Brain Derived Neurotrophic Factor (BDNF), Apolipoprotein (APOE) and Catechol-O-Methyltransferase (COMT). These involve a replacement of cystine by arginine (APOEε4) or valines by 1 or 2 methionines (BDNF:val⁶⁶met, met⁶⁶met; COMT:val¹⁵⁸met; met¹⁵⁸met). However, the implications of these polymorphisms on post-stroke UL motor improvement specifically have not yet been elucidated.</p><p><strong>Objective: </strong>Examine the influence of genetic polymorphism on post-stroke UL motor improvement.</p><p><strong>Design: </strong>Systematic Review and Meta-Analysis.</p><p><strong>Methods: </strong>We conducted a systematic search of the literature published in English language. The modified Downs and Black checklist helped assess study quality. We compared change in UL motor impairment and activity scores between individuals with and without the polymorphisms. Meta-analyses helped assess change in motor impairment (Fugl Meyer Assessment) scores based upon a minimum of 2 studies/time point. Effect sizes (ES) were quantified based upon the Rehabilitation Treatment Specification System as follows: small (0.08-0.18), medium (0.19 -0.40) and large (≥0.41).</p><p><strong>Results: </strong>We retrieved 10 (4 good and 6 fair quality) studies. Compared to those with BDNF val⁶⁶met and met⁶⁶met polymorphism, meta-analyses revealed lower motor impairment (large ES) in those without the polymorphism at intervention completion (0.5, 95% CI: 0.11-0.88) and at retention (0.58, 95% CI:0.06-1.11). The presence of CoMT val¹⁵⁸met or met¹⁵⁸met polymorphism had similar results, with lower impairment (large ES ≥1.5) and higher activity scores (large ES ranging from 0.5-0.76) in those without the polymorphism. Presence of APOEε4 form did not influence UL motor improvement.</p><p><strong>Conclusion: </strong>Polymorphisms with the presence of 1 or 2 met alleles in BDNF and COMT negatively influence UL motor improvement.</p><p><strong>Registration: </strong>https://osf.io/wk9cf/.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241266601"},"PeriodicalIF":2.6,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early clinical response and complications of therapeutic plasma exchange in central nervous system demyelinating diseases.","authors":"Mehran Rashidi, Saba Naghavi, Neda Ramezani, Fereshteh Ashtari, Vahid Shaygannejad, Sayed Mohsen Hosseini, Iman Adibi","doi":"10.1177/11795735241262738","DOIUrl":"10.1177/11795735241262738","url":null,"abstract":"<p><strong>Background: </strong>Appropriate treatment reduces the severity and duration of relapses in demyelinating diseases of Central Nervous System (CNS). If high-dose corticosteroids treatment fails, therapeutic plasma exchange (TPE) is considered as a rescue treatment.</p><p><strong>Objectives: </strong>This study aimed to investigate early clinical response and complications of TPE and prognostic factors in CNS demyelinating relapses.</p><p><strong>Design: </strong>This prospective observational study was designed in a tertiary center during one year.</p><p><strong>Methods: </strong>All adult patients diagnosed corticosteroid-resistant Multiple Sclerosis (MS), NeuroMyelitis Optica Spectrum Disorder (NMOSD), idiotypic Transverse Myelitis or Clinical Isolated Syndrome relapses, were eligible. Clinical response is defined based on Expanded Disability Status Scale (EDSS) at discharge. Clinical and laboratory complications recorded.</p><p><strong>Results: </strong>Seventy-two patients were analyzed which 58.3% patients were female. MS was diagnosed for 61.1% of cases. Thirty-five patients (48.6%) responded and the mean differences of EDSS significantly decreased 0.60 score (CI95%:0.44-.77). Electrolyte imbalances and thrombocytopenia occurred in 80.6% and 55.6% of cases respectively and 40.3% of patients had systemic reactions. However, 26.4% patients experienced moderate to severe complications. In patients with moderate to severe disability, responders were younger (MD: 8.42 years, CI95%: 1.67-15.17) and had lower EDSS score at admission (median:6, IQR: 5.5-6 against 7.5 IQR: 6.5-8). The risk of failure was higher in active progressive MS patients compared with RRMS patients (OR: 6.06, CI 95%:1.37-26.76). Patients with thrombocytopenia were hospitalized more than others (MD: 1.5 days, CI 95%: 0-3). Females were more prone to hypokalemia and systemic reactions (OR: 3.11, CI 95%:1.17-8.24 and OR: 6.67, CI 95%:2.14-20.81 respectively).</p><p><strong>Conclusion: </strong>The most common indication of TPE was corticosteroid-resistant severe MS relapses. About half of the patients presented an early clinical response. Lower disability, younger age and RRMS diagnosis are prognostic factors of better response. One out of four patients experienced moderate to severe complications, mainly electrolyte imbalances and systemic reactions. Appropriate interventions against these complications should be considered during TPE, especially in females.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241262738"},"PeriodicalIF":2.6,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11188695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term, home-based transcranial direct current stimulation coupled with computerized cognitive training in frontotemporal dementia: A case report.","authors":"Donna C Tippett, Kyriaki Neophytou, Yuan Tao, Jessica Gallegos, Christopher Morrow, Chiadi U Onyike, Kyrana Tsapkini","doi":"10.1177/11795735241258435","DOIUrl":"10.1177/11795735241258435","url":null,"abstract":"<p><p>We present the case of a 62-year-old woman with probable behavioral variant of frontotemporal dementia (bvFTD) with cognitive/language deficits who demonstrated improved performance on cognitive/language testing and in functional tasks following long-term, home-based transcranial direct current stimulation (tDCS) coupled with computerized cognitive training (CCT). The patient underwent home-based tDCS (anode on the left prefrontal cortex and cathode on the right homologue) for 46 sessions over 10 weeks along with CCT. On post-treatment testing, the patient improved by 3 points on the Mini-Mental State Exam (MMSE) (23 to 26). She also showed improvement on several cognitive/language tasks, such as immediate recall of single words and word pairs, total accurate words in sentence repetition, delayed recall, semantic processing, and sentence level comprehension. There was no decline in several other cognitive and language tasks. Family members reported subjective improvements in expressiveness, communication, and interaction with others as well as increased attention to grooming and style which contrasted with her pre-treatment condition. This report suggests that home-based tDCS combined with CCT for an extended period may slow decline, and improve cognitive/language performance and everyday function in FTD.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241258435"},"PeriodicalIF":4.8,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11149448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The assistive potential of functional electrical stimulation to support object manipulation in functional upper extremity movements after stroke: A randomized cross-over study.","authors":"Chiara Höhler, Joachim Hermsdörfer, Klaus Jahn, Carmen Krewer","doi":"10.1177/11795735241247812","DOIUrl":"10.1177/11795735241247812","url":null,"abstract":"<p><strong>Background: </strong>After standard care, 55%-75% of patients after stroke show a persistent paresis of the upper limb (UL). Assistive devices are developed to increase the patients' level of independence in daily life.</p><p><strong>Objectives: </strong>To investigate the potential of Functional Electrical Stimulation (FES) to assist object manipulation in activities of daily life.</p><p><strong>Design: </strong>Seventeen patients after stroke were tested and analyzed in a randomized cross-over design.</p><p><strong>Methods: </strong>Functional grasping was assessed by means of the Action Research Arm Test (ARAT) and the modified Box and Block Test (mBBT), in one session with and another without FES assistance. The order of sessions was randomized. Patients' motivation was assessed after each session. Task performance and motivation were compared between conditions using the Wilcoxon test and subgroup analyses were performed for impairment severity by distribution-based mixed-factor analyses.</p><p><strong>Results: </strong>When analyzing the total ARAT, FES did not effectively assist the overall performance (<i>P</i> = .142), but did assist the performance of objects of the Grasp category (<i>P</i> = .020). Impairment severity showed an interaction with the orthotic effect (<i>P</i> = .012), as severely impaired patients profited from FES assistance and mild-moderately impaired did not. When focusing on the more functional items of the ARAT (i.e., excluding scores from thumb-middle and thumb-ring finger combinations), there was a significant orthotic effect of FES on task performance (<i>P</i> = .023). Further, there was an orthotic effect for the number of transported blocks in the mBBT (<i>P</i> = .033), exclusively prominent in the group of severely impaired patients. Functional Electrical Stimulation did not increase the patients' motivation (<i>P</i> = .959), which was high after both conditions.</p><p><strong>Conclusion: </strong>Functional Electrical Stimulation has the potential to support object manipulation, but is dependent on impairment severity and object type. To observe a consistent orthotic effect, features of the stimulator should be further developed to generate appropriate grasps and forces across subjects and objects.</p><p><strong>Trial registration: </strong>The trial was registered with the German Clinical Trials Register (DRKS00025889).</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241247812"},"PeriodicalIF":2.6,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From progression to progress: The future of multiple sclerosis.","authors":"Jiwon Oh, Paul S Giacomini, V Wee Yong, Fiona Costello, François Blanchette, Mark S Freedman","doi":"10.1177/11795735241249693","DOIUrl":"10.1177/11795735241249693","url":null,"abstract":"<p><p>Significant advances have been made in the diagnosis and treatment of multiple sclerosis in recent years yet challenges remain. The current classification of MS phenotypes according to disease activity and progression, for example, does not adequately reflect the underlying pathophysiological mechanisms that may be acting in an individual with MS at different time points. Thus, there is a need for clinicians to transition to a management approach based on the underlying pathophysiological mechanisms that drive disability in MS. A Canadian expert panel convened in January 2023 to discuss priorities for clinical discovery and scientific exploration that would help advance the field. Five key areas of focus included: identifying a mechanism-based disease classification system; developing biomarkers (imaging, fluid, digital) to identify pathologic processes; implementing a data-driven approach to integrate genetic/environmental risk factors, clinical findings, imaging and biomarker data, and patient-reported outcomes to better characterize the many factors associated with disability progression; utilizing precision-based treatment strategies to target different disease processes; and potentially preventing disease through Epstein-Barr virus (EBV) vaccination, counselling about environmental risk factors (e.g. obesity, exercise, vitamin D/sun exposure, smoking) and other measures. Many of the tools needed to meet these needs are currently available. Further work is required to validate emerging biomarkers and tailor treatment strategies to the needs of individual patients. The hope is that a more complete view of the individual's pathobiology will enable clinicians to usher in an era of truly personalized medicine, in which more informed treatment decisions throughout the disease course achieve better long-term outcomes.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241249693"},"PeriodicalIF":4.8,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11072059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.","authors":"Christoph Friedli, Nik Krajnc, Helly N Hammer, Stefanie Marti, Tobias Zrzavy, Maria E Evangelopoulos, Ioanna Kapsali, Paulus Rommer, Thomas Berger, Andrew Chan, Gabriel Bsteh, Robert Hoepner","doi":"10.1177/11795735241249644","DOIUrl":"10.1177/11795735241249644","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 (cluster of differentiation) monoclonal antibodies (mAbs) such as ocrelizumab (OCR) and ofatumumab (OFA) show a reduction mainly of B-lymphocytes, but also other lymphocyte subsets can be affected by these treatments. There is limited data on differences between lymphocyte subset counts of pwMS after treatment initiation with OCR or OFA.</p><p><strong>Objective: </strong>To compare lymphocyte subset counts after treatment initiation in pwMS treated with OCR and OFA.</p><p><strong>Methods: </strong>We analyzed 22 pwMS initiated on OFA and 56 sex-, age- and MS course matched pwMS initiated on OCR from 2 prospectively collected observational MS databases (Bern [n: OFA 14, OCR 44] and Vienna [n: OFA 8, OCR 12]) statistically comparing lymphocyte subset counts (Mann Whitney Test).</p><p><strong>Results: </strong>We found that pwMS treated with OCR showed a stronger reduction of CD20 B-lymphocytes (<i>P</i> = .001), and a trend towards lower counts of CD8⁺ T cells (<i>P</i> = .056) compared to pwMS treated with OFA, whereas reduction of total lymphocyte, CD4⁺ lymphocyte and NK cell count was equally distributed between both treatments.</p><p><strong>Conclusion: </strong>Different effects on lymphocyte subpopulations appear to be present in pwMS after treatment initiation with different anti-CD20 mAbs. Further studies are needed to determine potential effects on anti-CD20 treatment efficacy as well as treatment associated risks such as failed vaccinations and infections.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241249644"},"PeriodicalIF":4.8,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11072073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCL13 as a biomarker in the diagnostics of European lyme Neuroborreliosis - A prospective multicentre study in Austria.","authors":"Christoph Waiß, Barbara Ströbele, Uwe Graichen, Sascha Klee, Joshua Gartlehner, Estelle Sonntagbauer, Stephanie Hirschbichler, Alexander Tinchon, Emrah Kacar, Bianca Wuchty, Bianka Novotna, Zofia Kühn, Johann Sellner, Walter Struhal, Christian Bancher, Peter Schnider, Susanne Asenbaum-Nan, Stefan Oberndorfer","doi":"10.1177/11795735241247026","DOIUrl":"https://doi.org/10.1177/11795735241247026","url":null,"abstract":"<p><strong>Background: </strong>'Definite Neuroborreliosis (NB)' is diagnosed with the presence of NB-specific symptoms, cerebrospinal fluid (CSF) pleocytosis and an elevated <i>Borrelia Burgdorferi</i> antibody index. However, some diagnostic uncertainties exist. The B-cell chemokine CXCL13 represents an emerging biomarker for the diagnosis and treatment of NB because its intrathecal concentration rises prior to the Borrelia antibody index and drops rapidly after antibiotic therapy. Nevertheless, due to lacking prospective data, a definite CXCL13 cut-off for the diagnosis of NB is still pending.</p><p><strong>Objective: </strong>Definition of a CSF CXCL13 cut-off for the diagnosis of acute and untreated NB in a prospective study setting.</p><p><strong>Design and methods: </strong>This multicentre prospective study involved 6 neurological departments treating patients in the Lower Austria district (1.7 million inhabitants). The controls were patients scheduled for a spinal tap but not clinically diagnosed with NB. Demographic data, clinical characteristics and blood counts, as well as inflammatory CSF values and CSF CXCL13-concentration were analysed.</p><p><strong>Results: </strong>We recruited 440 adult patients, of whom 42 have been diagnosed as having an acute and untreated 'definite NB'. Three hundred ninety-eight patients were assigned to the control group. The median intrathecal CXCL13 concentration was 2384 pg/ml for patients with NB and 0 pg/ml for controls. The difference was highly statistically significant (<i>P</i> ≤ .001). A CSF CXCL13 cut-off of 271 pg/ml resulted in a sensitivity of 95.2% and a specificity of 97.2% for the confirmation or exclusion of NB.</p><p><strong>Conclusion: </strong>Based on our results, we propose a CSF CXCL13 cut-off of 271 pg/ml with Euroimmun-Elisa for the diagnosis of acute and untreated NB. Due to its high sensitivity and specificity, CXCL13 is a strong candidate biomarker for routine NB assessment, especially in clinically unclear cases.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241247026"},"PeriodicalIF":4.8,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11067428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Awake craniotomies in South America: Advancements, challenges, and future prospects.","authors":"Alexandra Ramos-Marquez, Diego Fernando Gómez-Amarillo, Fernando Hakim, Edgar G Ordóñez-Rubiano","doi":"10.1177/11795735241249691","DOIUrl":"https://doi.org/10.1177/11795735241249691","url":null,"abstract":"","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241249691"},"PeriodicalIF":4.8,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11055481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}